List view / Grid view
Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment…
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
In this episode, we discuss the current advantages and limitations of using organoids, as well as where the field is heading.
US researchers innovate cancer diagnostics using Kinase Inhibitor Pulldown Assay, or KIPA, to search for proteins they could target to control tumour growth.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19 will impact the ways research is conducted. One outcome he posits is the acceleration of the digital transformation that was already occurring in pharmaceutical R&D.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
